| pubmed-article:19601709 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19601709 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:19601709 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:19601709 | lifeskim:mentions | umls-concept:C0002871 | lld:lifeskim |
| pubmed-article:19601709 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:19601709 | lifeskim:mentions | umls-concept:C0439211 | lld:lifeskim |
| pubmed-article:19601709 | lifeskim:mentions | umls-concept:C0937950 | lld:lifeskim |
| pubmed-article:19601709 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:19601709 | pubmed:dateCreated | 2009-8-25 | lld:pubmed |
| pubmed-article:19601709 | pubmed:databankReference | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19601709 | pubmed:abstractText | Darbepoetin alfa is effective in treating chemotherapy-induced anemia (CIA). Administration of subcutaneous darbepoetin alfa every 3 weeks (Q3W) could simplify treatment through synchronization with common Q3W chemotherapy regimens. We report results from a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy and safety of fixed-dose Q3W darbepoetin alfa in patients with a wide variety of tumor types who experienced CIA. | lld:pubmed |
| pubmed-article:19601709 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19601709 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19601709 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19601709 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19601709 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19601709 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19601709 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19601709 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:19601709 | pubmed:issn | 1473-4877 | lld:pubmed |
| pubmed-article:19601709 | pubmed:author | pubmed-author:TaylorKerryK | lld:pubmed |
| pubmed-article:19601709 | pubmed:author | pubmed-author:GanlyPeterP | lld:pubmed |
| pubmed-article:19601709 | pubmed:author | pubmed-author:TomitaDianneD | lld:pubmed |
| pubmed-article:19601709 | pubmed:author | pubmed-author:CharuVeenaV | lld:pubmed |
| pubmed-article:19601709 | pubmed:author | pubmed-author:HernandezEnri... | lld:pubmed |
| pubmed-article:19601709 | pubmed:author | pubmed-author:LillieTomT | lld:pubmed |
| pubmed-article:19601709 | pubmed:author | pubmed-author:DibenedettoJo... | lld:pubmed |
| pubmed-article:19601709 | pubmed:author | pubmed-author:ARANESP... | lld:pubmed |
| pubmed-article:19601709 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19601709 | pubmed:volume | 25 | lld:pubmed |
| pubmed-article:19601709 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19601709 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19601709 | pubmed:pagination | 2109-20 | lld:pubmed |
| pubmed-article:19601709 | pubmed:meshHeading | pubmed-meshheading:19601709... | lld:pubmed |
| pubmed-article:19601709 | pubmed:meshHeading | pubmed-meshheading:19601709... | lld:pubmed |
| pubmed-article:19601709 | pubmed:meshHeading | pubmed-meshheading:19601709... | lld:pubmed |
| pubmed-article:19601709 | pubmed:meshHeading | pubmed-meshheading:19601709... | lld:pubmed |
| pubmed-article:19601709 | pubmed:meshHeading | pubmed-meshheading:19601709... | lld:pubmed |
| pubmed-article:19601709 | pubmed:meshHeading | pubmed-meshheading:19601709... | lld:pubmed |
| pubmed-article:19601709 | pubmed:meshHeading | pubmed-meshheading:19601709... | lld:pubmed |
| pubmed-article:19601709 | pubmed:meshHeading | pubmed-meshheading:19601709... | lld:pubmed |
| pubmed-article:19601709 | pubmed:meshHeading | pubmed-meshheading:19601709... | lld:pubmed |
| pubmed-article:19601709 | pubmed:meshHeading | pubmed-meshheading:19601709... | lld:pubmed |
| pubmed-article:19601709 | pubmed:meshHeading | pubmed-meshheading:19601709... | lld:pubmed |
| pubmed-article:19601709 | pubmed:meshHeading | pubmed-meshheading:19601709... | lld:pubmed |
| pubmed-article:19601709 | pubmed:meshHeading | pubmed-meshheading:19601709... | lld:pubmed |
| pubmed-article:19601709 | pubmed:meshHeading | pubmed-meshheading:19601709... | lld:pubmed |
| pubmed-article:19601709 | pubmed:meshHeading | pubmed-meshheading:19601709... | lld:pubmed |
| pubmed-article:19601709 | pubmed:meshHeading | pubmed-meshheading:19601709... | lld:pubmed |
| pubmed-article:19601709 | pubmed:meshHeading | pubmed-meshheading:19601709... | lld:pubmed |
| pubmed-article:19601709 | pubmed:meshHeading | pubmed-meshheading:19601709... | lld:pubmed |
| pubmed-article:19601709 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19601709 | pubmed:articleTitle | Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia. | lld:pubmed |
| pubmed-article:19601709 | pubmed:affiliation | Temple University Hospital, Philadelphia, PA, USA. | lld:pubmed |
| pubmed-article:19601709 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19601709 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:19601709 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:19601709 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:19601709 | pubmed:publicationType | Clinical Trial, Phase III | lld:pubmed |
